BCYC Stock Overview
A clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Bicycle Therapeutics plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$22.98 |
52 Week High | US$28.91 |
52 Week Low | US$12.54 |
Beta | 0.90 |
1 Month Change | 1.10% |
3 Month Change | -11.55% |
1 Year Change | -4.45% |
3 Year Change | -22.81% |
5 Year Change | 96.41% |
Change since IPO | 91.50% |
Recent News & Updates
Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Recent updates
Bicycle Therapeutics Boosts Balance Sheet To Navigate Data Desert
May 24Shareholders May Not Be So Generous With Bicycle Therapeutics plc's (NASDAQ:BCYC) CEO Compensation And Here's Why
May 10Analysts' Revenue Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Are Surging Higher
May 04Does Bicycle Therapeutics (NASDAQ:BCYC) Have A Healthy Balance Sheet?
Apr 19Bicycle: 2nd Half Of 2024 Data Could Provide Significant Inflection Point
Mar 12Bicycle Therapeutics (NASDAQ:BCYC) Is Using Debt Safely
Jan 04Newsflash: Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Revenue Forecasts
Nov 07The Bicycle Therapeutics plc (NASDAQ:BCYC) Analysts Have Been Trimming Their Sales Forecasts
May 14Industry Analysts Just Upgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Revenue Forecasts By 26%
Mar 31Is Bicycle Therapeutics (NASDAQ:BCYC) Using Debt In A Risky Way?
Mar 09Time To Worry? Analysts Just Downgraded Their Bicycle Therapeutics plc (NASDAQ:BCYC) Outlook
Nov 08Bicycle Therapeutics: Exploring An Intriguing Developmental Platform
Oct 08Bicycle Therapeutics initiated Outperform at Cowen citing drug platform
Aug 31Bicycle to get $10M as Genentech uses option for new program under cancer drug collaboration
Jul 12Is Bicycle Therapeutics (NASDAQ:BCYC) Weighed On By Its Debt Load?
Jul 10Bicycle Therapeutics: Promising Early-Stage Cancer Drug Developer
Jul 05Bicycle Therapeutics: Trying To Catch This Falling Knife
Apr 17Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Apr 11Bicycle Therapeutics: A Buy Ahead Of AACR Presentation
Mar 25Bicycle Therapeutics: An Oncology Play With Big Potential
Feb 28Bicycle Therapeutics (NASDAQ:BCYC) Has Debt But No Earnings; Should You Worry?
Nov 07Bicycle Therapeutics: Scaffolding Short Linear Peptides Into Bicycles
Aug 25The Consensus EPS Estimates For Bicycle Therapeutics plc (NASDAQ:BCYC) Just Fell Dramatically
Aug 07News Flash: Analysts Just Made A Sizeable Upgrade To Their Bicycle Therapeutics plc (NASDAQ:BCYC) Forecasts
May 08Bicycle Therapeutics EPS misses by $0.05, beats on revenue
May 06Some Analysts Just Cut Their Bicycle Therapeutics plc (NASDAQ:BCYC) Estimates
Mar 08Is Bicycle Therapeutics (NASDAQ:BCYC) A Risky Investment?
Feb 23Shareholder Returns
BCYC | US Biotechs | US Market | |
---|---|---|---|
7D | 6.4% | -2.9% | -0.6% |
1Y | -4.4% | 6.6% | 25.4% |
Return vs Industry: BCYC underperformed the US Biotechs industry which returned 7.4% over the past year.
Return vs Market: BCYC underperformed the US Market which returned 25.6% over the past year.
Price Volatility
BCYC volatility | |
---|---|
BCYC Average Weekly Movement | 7.6% |
Biotechs Industry Average Movement | 11.0% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 15.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: BCYC has not had significant price volatility in the past 3 months.
Volatility Over Time: BCYC's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2009 | 284 | Kevin Lee | www.bicycletherapeutics.com |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors.
Bicycle Therapeutics plc Fundamentals Summary
BCYC fundamental statistics | |
---|---|
Market cap | US$985.55m |
Earnings (TTM) | -US$168.16m |
Revenue (TTM) | US$41.61m |
23.6x
P/S Ratio-5.8x
P/E RatioIs BCYC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
BCYC income statement (TTM) | |
---|---|
Revenue | US$41.61m |
Cost of Revenue | US$159.42m |
Gross Profit | -US$117.81m |
Other Expenses | US$50.36m |
Earnings | -US$168.16m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -3.93 |
Gross Margin | -283.12% |
Net Profit Margin | -404.14% |
Debt/Equity Ratio | 8.7% |
How did BCYC perform over the long term?
See historical performance and comparison